Beijing Zhengda Oasis Medicine Technology

Beijing Zhengda Oasis Medicine Technology is a specialized pharmaceutical research and development company and a subsidiary of the CP Pharmaceutical Group (Sino Biopharmaceutical). Based in Beijing, the company focuses on the development of high-barrier generic drugs and innovative small molecule therapies across several therapeutic areas, including cardiovascular, anti-infective, and digestive diseases. It operates as a key research hub within its parent organization, leveraging advanced chemical synthesis and formulation platforms to bring cost-effective treatments to the Chinese market. The company has successfully developed and commercialized several significant products, including generic versions of tofacitinib and rivaroxaban, establishing itself as a leader in high-end pharmaceutical manufacturing in China.